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Background: The guanine nucleotide-binding protein, alpha stimulating (GNAS) gene has been associated with growth hormone 
(GH)-secreting pituitary adenoma. We investigated the prevalence of GNAS mutations in Korean patients with acromegaly and as-
sessed whether mutation status correlated with biochemical or clinical characteristics.
Methods: We studied 126 patients with acromegaly who underwent surgery between 2005 and 2014 at Severance Hospital. We per-
formed GNAS gene analysis and evaluated age, sex, hormone levels, postoperative biochemical remission, and immunohistochemi-
cal staining results of the tumor.
Results: GNAS mutations were present in 75 patients (59.5%). Patients with and without GNAS mutations showed similar age distri-
bution and Knosp classification. The proportion of female patients was 76.5% and 48.0% in the GNAS-negative and GNAS-mutation 
groups, respectively (P=0.006). In immunohistochemical staining, the GNAS-mutation group showed higher GH expression in pitu-
itary tumor tissues than the mutation-negative group (98.7% vs. 92.2%, P=0.015). Patients with GNAS mutations had higher preop-
erative insulin-like growth factor-1 levels (791.3 ng/mL vs. 697.0 ng/mL, P=0.045) and lower immediate postoperative basal (0.9 
ng/mL vs. 1.0 ng/mL, P=0.191) and nadir GH levels (0.3 ng/mL vs. 0.6 ng/mL, P=0.012) in oral glucose tolerance tests. Finally, the 
GNAS-mutation group showed significantly higher surgical remission rates than the mutation-negative group, both at 1 week and 6 
months after surgical resection (70.7% vs. 54.9%, P=0.011; 85.3% vs. 82.4%, P=0.007, respectively).
Conclusion: GNAS mutations in GH-secreting pituitary tumors are associated with higher preoperative insulin-like growth factor-1 
levels and surgical remission rates and lower immediate postoperative nadir GH levels. Thus, GNAS mutation status can predict sur-
gical responsiveness in patients with acromegaly.
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INTRODUCTION
Acromegaly is a chronic disorder resulting from an excess of 
growth hormone (GH), and it is most commonly caused by GH-
secreting pituitary adenomas. Hypersecretion of GH results in 
increased production of insulin-like growth factor-1 (IGF-1), 
leading to a multisystem disease characterized by somatic over-
growth, multiple comorbidities, and premature mortality [1,2].
Acromegaly is a rare disease and related genes have been 
studied. Although most cases of acromegaly occur sporadically, 
more than 50% of cases of childhood-onset acromegaly are as-
sociated with a genetic cause. Several germline mutations are 
associated with acromegaly, including those in multiple endo-
crine neoplasia type 1 (MEN1), protein kinase A regulatory sub-
unit 1α (PRKARIA), aryl hydrocarbon receptor-interacting pro-
tein (AIP), and G-protein coupled receptor 101 (GPR101) 
genes. X-linked acrogigantism and a few related somatic muta-
tions have also been reported [3-5]. The most commonly identi-
fied somatic mutations in acromegaly are activating mutations 
of the guanine nucleotide-binding protein, alpha stimulating 
(GNAS) gene [6]. A gain-of-function mutation in GNAS increas-
es cyclic adenosine monophosphate (cAMP) synthesis and re-
sults in increased cell proliferation and GH secretion. Hotspot 
mutations in GNAS have been identified at codon 201, wherein 
arginine is replaced by cysteine, histidine, or serine, and in co-
don 227, wherein glutamine is replaced by arginine or leucine 
[7,8]. Approximately 30% to 40% of patients with sporadic ac-
romegaly have GNAS mutations [6]. Patients with acromegaly 
with GNAS mutations tend to have high GH and IGF-1 levels 
and show a favorable response to somatostatin analogs (SSAs) 
[9,10].
However, limited data have been reported for Asian popula-
tions. The prevalence of these mutations varies according to pa-
tient cohorts, ranging from 4.4% in Japanese patients [11] to 
55% in Chinese patients [12]. In addition, many studies on the 
clinical outcomes of acromegaly associated with GNAS muta-
tions have been conducted; however, only a few have analyzed 
the relationship between the surgical remission rate and GNAS 
mutations. Therefore, in this study, we investigated the preva-
lence of GNAS mutations in Korean patients with acromegaly 
and assessed whether mutation status correlated with biochemi-
cal or clinical characteristics. Furthermore, we analyzed the re-




We enrolled Korean patients with acromegaly who underwent 
transsphenoidal adenomectomy (TSA) between January 2005 
and May 2014 at Severance Hospital, Seoul, South Korea. Pa-
tients with a family history or germline mutation were excluded. 
All TSAs were performed by one neurosurgeon (S.H.K.). In to-
tal, 138 patients were enrolled and 12 of them were excluded 
because of insufficient DNA for analysis (Fig. 1).
Clinical data were retrospectively collected from patients’ 
medical records. Pituitary tumors were classified based on the 
dynamic magnetic resonance imaging (MRI) of the sellar and 
parasellar regions based on the Knosp classification. According 
to a previous study [13,14], Knosp grades 3 and 4 were classi-
fied as having cavernous sinus invasion. Tumor size was deter-
mined from the preoperative MRI report and recorded as the 
maximal tumor diameter. Immunohistochemical (IHC) staining 
of the operated pituitary tumors was performed, following 
which they were classified as focal GH, weak GH, and GH by 
two pathologists. Focal GH was defined as the expression of 
GH in less than 10% of the total tumor area, and weak GH was 
defined as low GH expression compared to the surrounding 
normal GH-secreting cells. The other tumors were classified as 
GH. Proliferative activity of the tumor cells was determined by 
calculating the percentage of cells exhibiting the Ki-67 antigen. 
As the Ki-67 index was measured from 2010 onwards, only the 
Retrospective analysis of records of 138 patients
who underwent TSA during 2005–2014
126 Patients were included
75 Patients with  
GNAS mutation
51 Patients with no 
GNAS mutation
12 Patients were excluded
- Gene mutation was not checked
Sanger sequencing for GNAS
Fig. 1. Flow chart of the study population. TSA, transsphenoidal 
adenomectomy; GNAS, guanine nucleotide-binding protein, alpha 
stimulating.
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data from 97 patients who underwent surgery after 2010 were 
analyzed.
Immediate postoperative dynamic MRI of the sella was con-
ducted within 48 hours after TSA to determine whether surgical 
resection was complete, and the postoperative MRI findings 
were compared with those of MRI conducted 1 year following 
TSA. Subsequently, MRI was performed annually to find any 
evidence of recurrence and every 2 or 3 years if the patient 
achieved biochemical remission. Surgical remission was de-
fined as a nadir serum GH level of <1 ng/mL based on the re-
sult of the 75-g oral glucose tolerance test (OGTT), and age- 
and sex-matched normal IGF-1 levels. This study was approved 
by the Institutional Review Board of the Yonsei University Col-
lege of Medicine (4-2019-1185). Informed consent was ob-
tained from all individual participants included in this study.
Endocrinological evaluation
Before surgery, serum GH and IGF-1 levels were measured 
from serum obtained during the 75-g OGTT. OGTT was per-
formed 1 week after TSA, every 6 months for 3 years, and then 
annually. Before February 2010, GH levels were measured us-
ing an immunoradiometric assay (hGH 100T Kit, Nichols Insti-
tute, San Juan Capistrano, CA, USA) with a sensitivity of 0.02 
ng/mL. The within-assay coefficient of variation (CV) ranged 
from 2.8% to 4.2%, and the interassay CV varied from 3.5% to 
7.2%. After February 2010, GH levels were measured using an 
immunoradiometric assay (hGH-RIACT, CIS Bio International, 
Gif-sur-Yvette, France) with a sensitivity of 0.03 mIU/mL. The 
within-assay CV ranged from 1.3% to 2.1%, and the interassay 
CV varied from 3.8% to 5.0%. The World Health Organiza-
tion’s international standard (98/574) was used to measure the 
GH level.
Before July 2005, IGF-1 levels were measured using an im-
munoradiometric assay system (DSL-5600 Active, Diagnostic 
Systems Laboratories, Webster, TX, USA) with 0.80 ng/L sen-
sitivity. The within-assay CV ranged from 1.5% to 3.4%, and 
the interassay CV varied from 1.5% to 8.2%. After July 2005, 
IGF-1 levels were measured using an immunoradiometric assay 
system (IGF-1 NEXT IRMA CT, Biocode Hycel, Liège, Bel-
gium), with a minimum detectable IGF-1 concentration of 1.25 
ng/L. The interassay and within-assay CV ranges of IGF-1 were 
7.4% to 9.1% and 2.6% to 4.4%, respectively [15].
GNAS gene analysis
Tumor DNA was extracted using QIAamp DNA FFPE Tissue 
Kit (50) according to the manufacturer’s instructions. GNAS 
gene analysis was performed by amplifying the regions contain-
ing two sites of activating somatic mutations in codons 201 and 
227 using primers (forward: GCTTCCTGGACAAGATCGAC, 
reverse: CTCCACAAACCTGTTGTTCCA; short forward: GC-
CGAGCGATCAGGTGTG; short reverse: GGAAGTTGACTT-
TGTCCACC) designed to cover both hotspot mutations. 
The following polymerase chain reaction thermocycling con-
ditions were used: initial denaturation at 94°C for 5 minutes, 
followed by 35 cycles of denaturation at 94°C for 30 seconds, 
annealing at 58°C for 1 minute, extension at 72°C for 1 minute, 
and a final extension step at 72°C for 7 minutes. Gene muta-
tions were evaluated by conventional Sanger sequencing.
Statistical analysis
SPSS Statistics version 25 (IBM Corp., Armonk, NY, USA) 
was used for all statistical analyses. Continuous variables are 
expressed as median (interquartile range [IQR]). The Mann-
Whitney U test was used for the analysis of continuous vari-
ables to compare groups based on gene mutations. Categorical 
variables were analyzed using the Fisher exact test. Multivariate 
binary logistic regression analysis was performed to analyze 
risk factors associated with surgical remission in patients with 
acromegaly. A P value <0.05 was considered to indicate statis-
tical significance.
RESULTS
Baseline characteristics of the study population
The characteristics of the 126 patients are shown in Table 1. The 
median age was 42 years (IQR, 35 to 50) at diagnosis, and 60% 
of the patients were female. The median tumor size was 15 mm. 
The median follow-up duration after TSA was 75.5 months 
(IQR, 63.3 to 97.4). Total removal after TSA was achieved in 
91.3% of patients, while subtotal removal was achieved in 8.7% 
of patients. Most of the tumors (95.2%) were GH-positive in 
IHC staining.
Patients were classified according to the presence of GNAS 
mutations and their clinical characteristics were compared. 
GNAS mutations were present in 75 of the 126 acromegaly pa-
tients (59.5%). Of the GNAS mutations, 86.7% were located at 
codon 201, while the rest of them were located at codon 227. 
Patients with and without GNAS mutations were similar with 
regard to age distribution and Knosp classification. The muta-
tion-negative group was 76.5% female, and the mutation-posi-
tive group was 48.0% female (P=0.006). There was no signifi-
cant difference in tumor size according to GNAS mutations. No-
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tably, the GNAS mutation-positive group had a higher preva-
lence of GH positivity in IHC staining than the mutation-nega-
tive group (97.3% vs. 92.2%, P=0.015).
Immediate postoperative biochemical remission
The median preoperative serum GH and IGF-1 levels were 15.1 
and 753.1 ng/mL, respectively (Table 2). One week after TSA, 
the median nadir GH level during OGTT was 0.4 ng/mL and the 
median IGF-1 level was 342.1 ng/mL. Six months after TSA, 
the median nadir GH level during OGTT was 0.9 ng/mL, and 
the median IGF-1 level was 250.3 ng/mL.
The median preoperative serum GH levels were similar in the 
mutation-positive and -negative groups (14.7 ng/mL vs. 16.1 
ng/mL, respectively). The median preoperative IGF-1 level was 
significantly higher in the mutation-positive group than in the 
mutation-negative group (770.9 ng/mL vs. 697.0 ng/mL, re-
spectively; P=0.045).
Immediately after TSA, median basal GH and nadir GH lev-
els on OGTT were lower in the GNAS mutation-positive group 
than in the mutation-negative group. The median immediate 
postoperative IGF-1 level was not significantly different be-
tween the mutation-positive (336.0 ng/mL) and mutation-nega-
tive (348.3 ng/mL) groups (P=0.393). Six months after TSA, 
the median postoperative IGF-1 level decreased further com-
pared to that immediately after TSA (mutation-positive group 
254.8 ng/mL vs. mutation-negative group 243.3 ng/mL, P=  
0.767) (Table 2). Median GH levels immediately after TSA—in 
particular, the levels at 24, 48, and 72 hours after TSA—were 
significantly lower in the GNAS mutation-positive group than in 
the mutation-negative group (Table 3).





No. of patients 126 51 (40.5) 75 (59.5)
Age, yr 42 (35–50) 43 (36–53) 41 (34–48) 0.098
Sex 0.006
   Male 51 (40.5) 12 (23.5) 39 (52.0)
   Female 75 (59.5) 39 (76.5) 36 (48.0)
Follow-up duration, mo 75.5 (63.3–97.4) 73.4 (52.5–95.9) 86.0 (69.8–99.8) 0.051
Size, mm 15 (10.75–20.0) 15 (12–23) 14 (10–18) 0.052
Knosp classification 0.100
   0 18 (14.3) 5 (9.8) 13 (17.3)
   1 48 (38.1) 21 (41.2) 27 (36.0)
   2 41 (32.5) 13 (25.5) 28 (37.3)
   3a 12 (9.5) 6 (11.8) 6 (8.0)
   3b 1 (0.8) 1 (2.0) 0 
   4 6 (4.8) 5 (9.8) 1 (1.3)
Immunohistochemical staining 0.015
   Focal GH 1 (0.8) 1 (2.1) 0 
   Weak GH 5 (4.0) 3 (5.9) 2 (2.6)
   GH 120 (95.2) 47 (92.2) 73 (97.3)
Ki-67 staining, % 97 41 56 0.604
   <1 44 20 24
   1–2 38 14 24
   2–3 13 7 6
   >3 2 0 2
Values are expressed as number (%) or median (interquartile range).
GNAS, guanine nucleotide-binding protein, alpha stimulating; GH, growth hormone.
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Long-term surgical outcomes
The surgical remission rate was 64.3% immediately after TSA 
and 84.1% at 6 months after TSA. The surgical remission rate 
immediately after TSA was higher in the GNAS mutation-posi-
tive group than in the mutation-negative group (70.7% vs. 
54.9%, P=0.011). Similarly, the surgical remission rate at 6 
months after TSA was higher in the mutation-positive group than 
in the mutation-negative group (85.3% vs. 82.4%, P=0.007).
Six months after TSA, 20 patients were not cured. Patients 
with residual tumors were treated with gamma knife radiosur-
gery (GKS) and medications such as SSAs or dopamine ago-
nists. When followed up in July 2019, eight patients were still 
on medication (Table 4). Of these, three patients with a GNAS 
mutation were treated with cabergoline, which controlled the 
small remnant tumor well, and five with no GNAS mutation 
were treated with GKS, reoperation, and SSAs. The statistical 
significance of the results is unclear because of the small num-
ber of patients. 
Changes in other pituitary hormones after TSA
At 6 months after TSA, normal pituitary function was main-
tained in 52 patients (41.2%) and improvement of preoperative 
hypopituitarism was noted in 59 patients (46.8%). Hypopituita-
rism persisted in six patients (4.7%) and became aggravated in 
nine patients (7.1%). Hormonal changes were not related to the 
presence of a GNAS mutation (P=0.112).
Recurrence
During the follow-up period, three patients without a GNAS 






TSA, total/subtotal 115 (91.3)/11 (8.7) 43 (84.3)/8 (15.7) 72 (96.0)/3 (4.0) 0.075
Preoperative OGTT
   Basal GH, ng/mL 15.1 (6.9–32.3) 16.1 (5.9–32.2) 14.7 (7.5–32.4) 0.785
   Nadir GH, ng/mL 11.0 (5.1–23.8) 8.7 (4.6–23.3) 11.4 (6.0–24.3) 0.380
   IGF-1, ng/mL 753.1 (600.0–899.2) 697.0 (561.2–884.4) 770.9 (647.0–903.5) 0.045
Immediate postoperative OGTT
   Basal GH, ng/mL 0.9 (0.5–1.8) 1.0 (0.6–2.6) 0.9 (0.4–1.7) 0.191
   Nadir GH, ng/mL 0.4 (0.1–0.9) 0.6 (0.2–1.5) 0.3 (0.1–0.7) 0.012
   IGF-1, ng/mL 342.1 (280.9–467.6) 336.0 (256.4–494.9) 348.3 (292.9–435.8) 0.393
   Remission 81 (64.3) 28 (54.9) 53 (70.7) 0.011
Postoperative OGTT at 6 mo
   Basal GH, ng/mL 0.13 (0.1–0.3) 1.1 (0.4–2.6) 0.7 (0.1–2.1) 0.125
   Nadir GH, ng/mL 0.9 (0.2–2.5) 0.15 (0.1–0.3) 0.12 (0.1–0.3) 0.305
   IGF-1, ng/mL 250.3 (205.3–322.9) 243.3 (202.0–318.7) 254.8 (211.3–324.8) 0.767
   Remission 106 (84.1) 42 (82.4) 64 (85.3) 0.007
Values are expressed as number (%) or median (interquartile range).
GNAS, guanine nucleotide-binding protein, alpha stimulating; TSA, transsphenoidal adenomectomy; OGTT, oral glucose tolerance test; GH, growth 
hormone; IGF-1, insulin-like growth factor-1. 








   0 hr 2.00 (1.20–5.04) 2.70 (1.00–8.50) 0.648
   12 hr 0.95 (0.45–1.78) 0.70 (0.40–1.33) 0.131
   24 hr 1.10 (0.48–1.94) 0.68 (0.42–1.27) 0.047
   48 hr 1.08 (0.52–1.89) 0.70 (0.38–1.20) 0.043
   72 hr 0.99 (0.53–1.90) 0.74 (0.33–1.22) 0.011
Values are expressed as median (interquartile range).
GNAS, guanine nucleotide-binding protein, alpha stimulating.
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mutation showed recurrence of acromegaly. The first case was a 
29-year-old female patient who underwent subtotal adenomec-
tomy and continued medication. However, the size of the resid-
ual tumor increased, as shown in an MRI scan. She underwent 
GKS and is still on medication. The second case was a 38-year-
old female patient, who underwent total resection; however, 1 
year after TSA, a recurrent tumor was observed in an MRI scan. 
The third case was a 31-year-old female patient who was cured 
after TSA, but a newly developed tumor was found in a follow-
up MRI scan. The second and third cases also underwent GKS. 
There was no recurrence in the GNAS-mutation group.
Factors associated with surgical remission in acromegaly 
patients
Multivariate logistic regression analysis was used to analyze the 
factors associated with surgical remission in patients with acro-
megaly. The results showed that preoperative IGF-1 levels (odds 
ratio [OR], 1.004; 95% confidence interval [CI], 1.000 to 1.008; 
P=0.034) and cavernous sinus invasion (OR, 6.202; 95% CI, 
1.192 to 32.262; P=0.030) were significantly associated with 
surgical remission in patients with acromegaly. GNAS mutation-
negative patients were less likely to experience surgical remis-
sion, although this correlation was not significant (OR, 0.1192; 
95% CI, 0.035 to 1.058; P=0.058) (Table 5).
DISCUSSION
In this study, we showed the prevalence of GNAS gene muta-
tions in Korean patients with acromegaly and investigated the 
clinical characteristics and surgical remission rate of patients 





















1 44/F Yes 20 2 35.85 1,015.7 0.46 229.4 No Cabergoline 2 mg/wk
2 39/M Yes 12   3a 24.5 1,423 0.5 323 No Cabergoline 2 mg/wk
3 36/F Yes 19 0 23.6 852.8 0.99 296.8 No Cabergoline 2 mg/wk
4 50/F No 12 1 18.3 398.5 1 297 No Octreotide LAR 20 mg every 4 wk
5 36/F No 30 4 19.29 884.4 0.96 263.8 Yes GKS→cabergoline 2 mg/wk
6 39/M No 35 4 70.8 774.1 1.7 365.1 Yes GKS→octreotide LAR 20 mg  
every 4 wk
7 58/F No 20 4 5.9 555.6 0.77 193.2 Yes GKS→lanreotide autogel 60 mg  
every 4 wk
8 29/F No 30 2 27.63 1,036.8 2.1 273.9 Yes Reoperation, GKS→octreotide  
LAR 30 mg every 4 wk
GNAS, guanine nucleotide-binding protein, alpha stimulating; GH, growth hormone; IGF-1, insulin-like growth factor-1; MRI, magnetic resonance im-
aging; LAR, long-acting release; GKS, gamma knife radiosurgery.
Table 5. Factors Associated with Surgical Remission in Patients 
with Acromegaly
Factor OR (95% CI) P value
Age, /1 year increment 0.984 (0.897–1.079) 0.731
Sex
   Male Reference
   Female 1.577 (0.262-9.481) 0.619
Preoperative random GH,  
/1 ng/mL increment 
0.913 (0.784–1.064) 0.243
Preoperative OGTT nadir GH, 
/1 ng/mL increment 
1.110 (0.941–1.309) 0.214
Preoperative IGF-1,  
/1 ng/mL increment 
1.004 (1.000–1.008) 0.034
Knosp classification
   Grade 0–2 Reference 
   Grade 3–4 1.004 (0.118–8.567) 0.997
Cavernous sinus invasion
   No invasion Reference
   Invasion 6.202 (1.192–32.262) 0.030
GNAS mutation
   No mutation Reference 
   Mutation 0.192 (0.035–1.058) 0.058
OR, odds ratio; CI, confidence interval; GH, growth hormone; OGTT, 
oral glucose tolerance test; IGF-1, insulin-like growth factor-1; GNAS, 
guanine nucleotide-binding protein, alpha stimulating.
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with GNAS mutations. GNAS mutations were found in 59.5% of 
patients, and most of them were located on codon 201 (86.7%). 
GNAS mutation-positive tumors showed a high degree of GH 
staining and high hormone levels. The postoperative biochemi-
cal response and surgical remission rates were significantly 
more favorable in the mutation-positive patients.
GNAS encodes the alpha subunit of G protein with GTPase 
activity. GNAS mutations cause reduced GTPase activity, result-
ing in a constitutively active cAMP-dependent protein kinase A 
(PKA) pathway. This increases the level of activated PKA, 
which activates cAMP reactive element-binding protein in the 
nucleus and further activates the Pit-1 transcription factor, pro-
moting GH synthesis and cell proliferation [6,16,17]. Because 
GNAS is associated with GH synthesis and secretion, most stud-
ies have focused on GNAS mutations for drug responsiveness in 
acromegaly patients. After surgery, SSAs are considered the pri-
mary medical therapeutic agents in patients with persistent acro-
megaly [2]. However, one-third of patients treated with SSAs do 
not achieve biochemical remission [18]. Several genetic factors 
are involved in the response to SSA treatment. Most studies have 
reported that the therapeutic response to SSA is favorable in 
GNAS mutation-positive patients; the response has also been 
found to be significant in a meta-analysis [9]. Although this 
study did not analyze the response to SSAs, GNAS mutation-
positive patients were biochemically controlled with cabergoline, 
which has been proven to be moderately effective in acromegaly. 
Several studies have also reported the tumor characteristics relat-
ed to GNAS mutations. Some studies reported that tumors with 
GNAS mutations were smaller and less invasive than those with-
out GNAS mutations [19,20]. In contrast, other studies have 
shown no significant difference in tumor size between tumors 
with and without GNAS mutations [21]. In our study, GNAS mu-
tation-positive tumors showed no significant difference in size, 
but showed a greater degree of GH staining and higher IGF-1 se-
cretion than mutation-negative tumors. Baseline GH levels were 
not significantly different between the GNAS mutation-positive 
and -negative groups, but the IGF-1 level was lower in the 
GNAS-negative group. This might be explained by the higher 
proportion of female patients in the GNAS-negative group and 
the influence of estrogen on hepatic IGF-1 synthesis [22,23].
Several clinical factors related to the surgical outcomes of ac-
romegaly have been investigated. According to current guide-
lines [2], tumor size, preoperative GH concentration, and the 
experience of the pituitary surgeon are important for achieving 
successful surgery. In previous studies, extensive surgical resec-
tion could achieve a high surgical remission rate, and younger 
age, the female sex, cavernous sinus invasion, and sparsely 
granulated adenoma were related to poor surgical outcomes. In 
addition, the immediate postoperative GH level and 1-week 
postoperative OGTT GH levels were suggested as good predic-
tors of surgical remission [15,24-27]. Few studies have com-
pared surgical outcomes according to genetic alterations associ-
ated with acromegaly. In this study, the surgical remission rate 
of GNAS mutation-positive tumors was higher than that of mu-
tation-negative tumors. There were more women among the 
GNAS mutation-negative patients, consistent with the previous 
findings that women show a poor prognosis [24].
One of the reasons for the high surgical remission rate of 
GNAS mutation-positive tumors is that an early diagnosis is pos-
sible in such tumors due to high IGF-1 hormone secretion. On 
average, the diagnosis of acromegaly takes several years, be-
cause clinical symptoms are nonspecific and progress slowly 
[28]. Early recognition is important for achieving a high treat-
ment success rate and avoiding long-term comorbidities [29]. 
GNAS mutation-positive tumors tend to be smaller and show a 
higher cure rate because of the short time required for diagnosis. 
The percentage of patients who underwent total resection sur-
gery for GNAS mutation-positive tumors was significantly high-
er than that of those who underwent total resection surgery for 
mutation-negative tumors. IHC staining results showed that tu-
mors with GNAS mutations mostly presented a high expression 
of GH in tumor tissues, in contrast to the frequent low expression 
of GH-positive cells in mutation-negative tumors. These results 
suggest that GNAS-mutant tumors are well-differentiated, which 
may enable efficient IGF-1 secretion, while mutation-negative 
tumors might have a heterogeneous cell population.
A major strength of this study is that it is the first to compare 
the surgical remission rate according to GNAS mutation status. 
Since only one senior neurosurgeon performed all operations, 
there was minimal bias related to the surgical technique or 
method. In addition, the findings of this study are significant in 
that recurrence and long-term outcomes were observed for more 
than 5 years after surgery. However, there are also some limita-
tions to our study. Because this study was retrospective in nature 
and conducted at a single center, the number of patients was 
limited. Further prospective studies with a larger number of ac-
romegaly patients could provide insights into the clinical signif-
icance of GNAS mutations and their relationship with surgical 
outcomes. Second, we performed Sanger sequencing targeting 
two known hotspot mutations. Some patients with GNAS muta-
tions may have therefore been included in the GNAS-naïve 
group. Although numerous studies on GNAS have been per-
Link between GNAS Mutations and Acromegaly Outcome
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formed, similar rates of GNAS mutation-positive tumors have 
been observed regardless of the method of genetic testing 
[7,11,19,20,30,31], indicating that it is sufficient to analyze the 
hotspot mutations. Third, the granulation pattern was not ana-
lyzed. The granulation pattern of pituitary adenoma is consid-
ered an important determinant of prognosis and surgical remis-
sion [26,27]; hence, further study is needed.
In conclusion, we demonstrated the prevalence of GNAS muta-
tions in Korean patients with acromegaly. GNAS mutations 
showed a distinct phenotype and high surgical remission rates. 
Identifying GNAS mutations would be helpful for predicting the 
clinical features and prognosis of patients with acromegaly after 
TSA.
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